CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: In vitro treatment with 0.6 μM imatinib and 1.5 μM rosuvastatin in combination reduced cell viability compared to the single treatments; however, rosuvastatin alone induced cell death (<20% cell viability) in both healthy control and CML CD34+ stem/progenitor cells [69].